Cingulate Inc
CINGW0.106USD
+0.010+10.10%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de Cingulate Inc Compañía
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Información de la empresa
Símbolo de cotizaciónCINGW
Nombre de la empresaCingulate Inc
Fecha de salida a bolsaOct 07, 2021
Director ejecutivoDr. Shane J. Schaffer, Pharm.D.
Número de empleados- -
Tipo de seguridadCompany Warrant
Fin del año fiscal- -
Dirección1901 W. 47Th Place
CiudadKANSAS CITY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal66205
Teléfono19139422300
Sitio Webhttps://www.cingulate.com/
Símbolo de cotizaciónCINGW
Fecha de salida a bolsaOct 07, 2021
Director ejecutivoDr. Shane J. Schaffer, Pharm.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Dr. Shane J. Schaffer, Pharm.D.
Dr. Shane J. Schaffer, Pharm.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Laurie A. Myers, Ph.D.
Dr. Laurie A. Myers, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Independent Director
Independent Director
--
--
Dr. Matthew N. Brams, M.D.
Dr. Matthew N. Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Dr. Shane J. Schaffer, Pharm.D.
Dr. Shane J. Schaffer, Pharm.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Laurie A. Myers, Ph.D.
Dr. Laurie A. Myers, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Other
100.00%
Accionistas
Accionistas
Proporción
Other
100.00%
Tipos de accionistas
Accionistas
Proporción
Other
100.00%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
12
238.84K
0.00%
-824.25K
2025Q1
12
238.84K
0.00%
-824.25K
2024Q4
11
230.16K
0.00%
-848.35K
2024Q3
11
526.73K
0.00%
-559.74K
2024Q2
11
1.54M
0.00%
-29.99K
2024Q1
10
1.52M
0.00%
-577.42K
2023Q4
10
2.04M
0.00%
-3.83K
2023Q3
9
2.05M
0.00%
-52.84K
2023Q2
9
2.10M
0.00%
-175.37K
2023Q1
9
2.28M
0.00%
-7.12K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Hudson Bay Capital Management LP
210.80K
0%
--
--
Mar 31, 2025
Citadel Advisors LLC
12.58K
0%
-2.08K
-14.17%
Mar 31, 2025
GoalVest Advisory, LLC
3.00K
0%
--
--
Mar 31, 2025
Armistice Capital LLC
--
0%
-1.71K
-100.00%
Mar 31, 2025
Altium Capital Management LP
--
0%
-270.00K
-100.00%
Dec 31, 2024
Lynwood Capital Management Inc.
--
0%
-50.00K
-100.00%
Dec 31, 2023
Sabby Management, LLC
--
0%
-458.52K
-100.00%
Sep 30, 2024
Warberg Asset Management LLC
--
0%
-43.16K
-100.00%
Sep 30, 2024
Virtu Americas LLC
--
0%
-11.16K
-100.00%
Dec 31, 2024
BofA Global Research (US)
--
0%
-100.00
-100.00%
Sep 30, 2024
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
